|
US5945098A
(en)
|
1990-02-01 |
1999-08-31 |
Baxter International Inc. |
Stable intravenously-administrable immune globulin preparation
|
|
US5919452A
(en)
|
1991-03-18 |
1999-07-06 |
New York University |
Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
|
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
US5656272A
(en)
|
1991-03-18 |
1997-08-12 |
New York University Medical Center |
Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
|
|
US6284471B1
(en)
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
|
US5698195A
(en)
|
1991-03-18 |
1997-12-16 |
New York University Medical Center |
Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
|
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
|
ES2188657T3
(es)
|
1994-04-22 |
2003-07-01 |
Yamanouchi Pharma Co Ltd |
Sistema para la liberacion especifica en el colon de un farmaco.
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
MX336813B
(es)
|
1996-02-09 |
2016-02-02 |
Abbvie Biotechnology Ltd |
Anticuerpos humanos que ligan el tnfa humano.
|
|
GB9610992D0
(en)
|
1996-05-24 |
1996-07-31 |
Glaxo Group Ltd |
Concentrated antibody preparation
|
|
JP2000516594A
(ja)
|
1996-07-26 |
2000-12-12 |
スミスクライン・ビーチャム・コーポレイション |
免疫細胞介在全身性疾患の改良された治療法
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
PT917879E
(pt)
|
1997-11-22 |
2002-12-31 |
Roche Diagnostics Gmbh |
Processo melhorado para estabilizacao de proteinas
|
|
US6919372B1
(en)
|
1997-12-26 |
2005-07-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Sustained release pharmaceutical compositions
|
|
DE19814084B4
(de)
|
1998-03-30 |
2005-12-22 |
Lts Lohmann Therapie-Systeme Ag |
D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
|
|
DK2270044T3
(en)
|
1998-06-09 |
2015-01-26 |
Csl Behring Ag |
Liquid immunoglobulin G (IgG) product
|
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
|
EP1098885B9
(fr)
|
1998-07-23 |
2005-05-18 |
Fujisawa Pharmaceutical Co., Ltd. |
Composes d'imidazole et leur utilisation en tant qu'inhibiteurs d'adenosine deaminase
|
|
GB9824632D0
(en)
|
1998-11-10 |
1999-01-06 |
Celltech Therapeutics Ltd |
Biological compounds
|
|
DK1142905T3
(da)
|
1999-01-13 |
2006-09-18 |
Astellas Pharma Inc |
Hidtil ukendt depsipeptidforbindelse
|
|
HUP0200575A3
(en)
|
1999-03-25 |
2004-11-29 |
Abbott Gmbh & Co Kg |
Human antibodies that bind human il-12 and methods for producing
|
|
WO2007019398A1
(fr)
|
2005-08-03 |
2007-02-15 |
Advanced Cell Technology, Inc. |
Procedes ameliores de reprogrammation de cellules somatiques animales
|
|
US6716613B1
(en)
|
1999-11-11 |
2004-04-06 |
Yamanouchi Pharmaceutical Co., Ltd. |
Metalloprotease having aggrecanase activity
|
|
WO2001046392A2
(fr)
|
1999-12-22 |
2001-06-28 |
Oxford Glycosciences (Uk) Ltd. |
Substances
|
|
NZ520967A
(en)
|
2000-02-25 |
2004-04-30 |
Oxford Glycosciences Uk Ltd |
Use of breast cancer associated membrane proteins (BCMP) for treatment, prophylaxis and diagnosis of breast cancer
|
|
DE60130910T2
(de)
|
2000-04-17 |
2008-07-10 |
Ucb Pharma, S.A. |
Enamin-derivate als zell-adhäsionsmoleküle
|
|
JP2001322933A
(ja)
|
2000-05-15 |
2001-11-20 |
Ucb Sa |
Ｃｄ４０シグナル遮断剤
|
|
GB0013810D0
(en)
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
|
ATE368735T1
(de)
|
2000-12-18 |
2007-08-15 |
Astellas Pharma Inc |
Neue aggrecanase
|
|
WO2002053544A1
(fr)
|
2000-12-29 |
2002-07-11 |
Darwin Discovery Ltd. |
Utilisations pharmaceutiques et synthese de nicotinanilide-n-oxydes
|
|
CA2817619A1
(fr)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methodes pour administrer des anticorps anti-tnf.alpha.
|
|
GB0114644D0
(en)
|
2001-06-15 |
2001-08-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
|
DE60230266D1
(de)
|
2001-06-15 |
2009-01-22 |
Astellas Pharma Inc |
Phenylpyridincarbonyl piperazinderivate
|
|
EP2295081B1
(fr)
|
2001-06-26 |
2018-10-31 |
Amgen Inc. |
Anticorps OPGL
|
|
WO2003009740A2
(fr)
|
2001-07-24 |
2003-02-06 |
Biogen Idec Ma Inc. |
Methodes de traitement ou de prevention de troubles sclereux par l'usage d'agents se liant a cd2
|
|
TWI334439B
(en)
|
2001-08-01 |
2010-12-11 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
|
MXPA04001725A
(es)
|
2001-08-24 |
2005-04-11 |
Advanced Cell Tech Inc |
ANáLISIS DE SELECCION PARA IDENTIFICAR AGENTES INDUCTORES DE DIFERENCIACION Y PRODUCCION DE CELULAS DIFERENCIADAS PARA TERAPIA CELULAR.
|
|
US7241873B2
(en)
|
2001-09-25 |
2007-07-10 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
Recombinant anti-osteopontin antibody and use thereof
|
|
IL161677A0
(en)
|
2001-11-08 |
2004-09-27 |
Protein Design Labs |
Stable liquid pharmaceutical formulation of igg antibodies
|
|
ES2394018T3
(es)
|
2001-11-27 |
2013-01-15 |
Ucb Pharma S.A. |
Procedimientos para el diagnóstico y el tratamiento de cánceres derivados de células epiteliales
|
|
US7261892B2
(en)
|
2001-11-27 |
2007-08-28 |
Celltech R&D Limited |
Methods for diagnosis and treatment of epithelial-derived cancers
|
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
|
GB0208089D0
(en)
|
2002-04-09 |
2002-05-22 |
Oxford Glycosciences Uk Ltd |
Protein
|
|
US7638630B2
(en)
|
2002-04-30 |
2009-12-29 |
Ucb Pharma S.A. |
2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
|
|
WO2003099226A2
(fr)
|
2002-05-28 |
2003-12-04 |
Celltech R & D Limited |
Isomeres de position de peg d'anticorps, compositions les comprenant, et leur utilisation
|
|
CA2480619A1
(fr)
|
2002-06-06 |
2003-12-18 |
Masakatsu Kawakami |
Nouvelle oxydase
|
|
GB0214268D0
(en)
|
2002-06-20 |
2002-07-31 |
Celltech R&D Ltd |
Chemical compounds
|
|
EP1521581B1
(fr)
|
2002-07-02 |
2008-02-20 |
UCB Farchim S.A. |
Diarylmethylpiperazines utiles comme agents prophylactiques ou therapeutiques de la myocardite virale
|
|
WO2004009776A2
(fr)
|
2002-07-19 |
2004-01-29 |
Abbott Biotechnology Ltd. |
Traitement de troubles en relation avec le tnf$g(a)
|
|
GB0218800D0
(en)
|
2002-08-13 |
2002-09-18 |
Celltech R&D Ltd |
Chemical compounds
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
GB0222743D0
(en)
|
2002-10-01 |
2002-11-06 |
Celltech R&D Ltd |
Chemical compounds
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
EP1572976B1
(fr)
|
2002-11-21 |
2010-09-15 |
Celltech R & D, Inc. |
Modulation de reponses immunitaires
|
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
|
DK1581535T5
(da)
|
2003-01-09 |
2009-12-21 |
Astellas Pharma Inc |
Pyrrolopyridazinderivater
|
|
ES2625429T3
(es)
|
2003-01-23 |
2017-07-19 |
Esperion Therapeutics Inc. |
Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
|
|
EP1594423B1
(fr)
|
2003-02-14 |
2009-01-07 |
DePuy Spine, Inc. |
Dispositif et procede de fusion intervertebrale forme in-situ
|
|
EP1595952A4
(fr)
|
2003-02-19 |
2008-05-21 |
Astellas Pharma Inc |
Procede d'evaluation de l'effet antitumoral d'un inhibiteur d'histone desacetylase
|
|
US6805686B1
(en)
|
2003-05-06 |
2004-10-19 |
Abbott Laboratories |
Autoinjector with extendable needle protector shroud
|
|
EP1481683A1
(fr)
|
2003-05-30 |
2004-12-01 |
Yamanouchi Pharmaceutical Co. Ltd. |
Ligands ayant pour cible la P-selectine et compositions les comprenant
|
|
GB0312481D0
(en)
|
2003-05-30 |
2003-07-09 |
Celltech R&D Ltd |
Antibodies
|
|
CA2528602A1
(fr)
|
2003-06-20 |
2004-12-29 |
Celltech R & D Limited |
Derives de thienopyridone en tant qu'inhibiteurs de kinase
|
|
CA2528603A1
(fr)
|
2003-06-20 |
2004-12-29 |
Celltech R & D Limited |
Derives de thienopyridone en tant qu'inhibiteurs de kinase
|
|
ES2551439T5
(es)
|
2003-07-01 |
2018-11-08 |
Ucb Biopharma Sprl |
Fragmentos Fab de anticuerpos modificados
|
|
EP1640010A1
(fr)
|
2003-07-01 |
2006-03-29 |
Astellas Pharma Inc. |
Agent d'induction de croissance dans la masse osseuse
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
JP2007509123A
(ja)
|
2003-10-24 |
2007-04-12 |
セルテック アール アンド ディ リミテッド |
キナーゼ阻害剤としてのチエノ−ピリジノン誘導体
|
|
GB0325836D0
(en)
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
|
PT1685849E
(pt)
|
2003-11-20 |
2012-02-15 |
Astellas Pharma Inc |
Inibidores de pde4 para o tratamento da cistite intersticial
|
|
HUE026260T2
(en)
|
2003-11-21 |
2016-06-28 |
Ucb Biopharma Sprl |
A method for treating multiple sclerosis by inhibiting IL-17 activity
|
|
MX370489B
(es)
|
2004-01-09 |
2019-12-16 |
Pfizer |
Anticuerpos contra madcam.
|
|
JP2007104901A
(ja)
|
2004-01-16 |
2007-04-26 |
Astellas Pharma Inc |
関節リウマチ治療薬のスクリーニング法
|
|
JP2007104902A
(ja)
|
2004-01-16 |
2007-04-26 |
Astellas Pharma Inc |
関節リウマチ治療薬のスクリーニング法
|
|
US20190282622A1
(en)
|
2004-01-23 |
2019-09-19 |
Astellas Institute For Regenerative Medicine |
Modalities for the treatment of degenerative diseases of the retina
|
|
US7670624B2
(en)
|
2004-01-29 |
2010-03-02 |
Astella Pharma Inc. |
Gastrointestinal-specific multiple drug release system
|
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療ＴＮＦα相關失調症之多重可變劑量療法
|
|
US20070265289A1
(en)
|
2004-04-15 |
2007-11-15 |
Yoshinori Okamoto |
2-Aminopyrimidine Derivative
|
|
GB0411186D0
(en)
|
2004-05-19 |
2004-06-23 |
Celltech R&D Ltd |
Biological products
|
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
|
JP2007277093A
(ja)
|
2004-06-21 |
2007-10-25 |
Astellas Pharma Inc |
三環系化合物
|
|
JP2007269629A
(ja)
|
2004-06-21 |
2007-10-18 |
Astellas Pharma Inc |
キナゾリン誘導体
|
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
|
DE602005011286D1
(en)
|
2004-07-05 |
2009-01-08 |
Astellas Pharma Inc |
Pyrazolopyridinderivate
|
|
WO2006004191A1
(fr)
|
2004-07-05 |
2006-01-12 |
Astellas Pharma Inc. |
Derivés de pyrrolopyridazine qui inhibent la pde iv et le tnf alpha
|
|
WO2006038734A1
(fr)
|
2004-10-08 |
2006-04-13 |
Astellas Pharma Inc. |
Dérivés de la pyridazinone inhibiteurs de cytokines
|
|
US7893315B2
(en)
|
2004-11-04 |
2011-02-22 |
Advanced Cell Technology, Inc. |
Derivation of embryonic stem cells and embryo-derived cells
|
|
GB0425569D0
(en)
|
2004-11-19 |
2004-12-22 |
Celltech R&D Ltd |
Biological products
|
|
GB0425972D0
(en)
|
2004-11-25 |
2004-12-29 |
Celltech R&D Ltd |
Biological products
|
|
MY157915A
(en)
|
2004-12-21 |
2016-08-15 |
Centocor Inc |
Anti-il-12 antibodies, epitopes, compositions, methods and uses.
|
|
JP2008529968A
(ja)
|
2005-02-08 |
2008-08-07 |
国立循環器病センター総長 |
インスリン様成長因子−１（ｉｇｆ−１）を使用する慢性重症心不全を処置するための新規方法
|
|
WO2006088088A1
(fr)
|
2005-02-16 |
2006-08-24 |
Astellas Pharma Inc. |
Remède contre la douleur contenant un inhibiteur de la protéine rho-kinase
|
|
GB0506912D0
(en)
|
2005-04-05 |
2005-05-11 |
Celltech R&D Ltd |
Biological products
|
|
NZ595225A
(en)
|
2005-05-16 |
2013-05-31 |
Abbott Biotech Ltd |
Use of tnf inhibitor for treatment of erosive polyarthritis
|
|
EA013080B1
(ru)
|
2005-06-09 |
2010-02-26 |
Юсб Фарма С.А. |
2,6-хинолинильные производные, способы их получения и их применение
|
|
BRPI0611901A2
(pt)
|
2005-06-14 |
2012-08-28 |
Amgen, Inc |
composição, liofilizado, kit, e, processo para preparar uma composição
|
|
SI2452694T1
(sl)
|
2005-06-30 |
2019-05-31 |
Janssen Biotech, Inc. |
Protitelesa proti-IL-23, sestavki in postopki uporabe
|
|
GB0513852D0
(en)
|
2005-07-06 |
2005-08-10 |
Celltech R&D Ltd |
Biological products
|
|
GB0514779D0
(en)
|
2005-07-19 |
2005-08-24 |
Celltech R&D Ltd |
Biological products
|
|
EP2124062A1
(fr)
|
2005-08-12 |
2009-11-25 |
Astellas Pharma Inc. |
Procédé servant à identifier une protéine cible d'un agent et procédé servant à cribler un agent thérapeutique pour le diabète utilisant la protéine cible
|
|
EP1754476A1
(fr)
|
2005-08-18 |
2007-02-21 |
Schwarz Pharma Ag |
Lacosamide (SPM 927) pour le traitement de la myalgie, par exemple de la fibromyalgie
|
|
WO2007026950A1
(fr)
|
2005-09-01 |
2007-03-08 |
Astellas Pharma Inc. |
Nouveaux composes
|
|
ES2382879T3
(es)
|
2005-09-14 |
2012-06-14 |
Ucb Pharma, S.A. |
Conjugado de anticuerpo - polímero de peine.
|
|
GB0520169D0
(en)
|
2005-10-04 |
2005-11-09 |
Celltech R&D Ltd |
Biological products
|
|
CN103336129A
(zh)
|
2005-11-01 |
2013-10-02 |
阿布维生物技术有限公司 |
使用生物标志物诊断强直性脊柱炎的方法和组合物
|
|
EP1790664A1
(fr)
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
|
|
GB0523954D0
(en)
|
2005-11-24 |
2006-01-04 |
Ucb Celltech |
Bioassays
|
|
WO2007060411A1
(fr)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anticorps anti-tnf alpha qui inhibent sélectivement le signal tnf alpha par le p55r
|
|
SI1960430T1
(sl)
|
2005-12-09 |
2015-01-30 |
Ucb Pharma, S.A. |
Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6
|
|
CN102887955A
(zh)
|
2006-04-05 |
2013-01-23 |
艾博特生物技术有限公司 |
抗体纯化
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
US9399061B2
(en)
|
2006-04-10 |
2016-07-26 |
Abbvie Biotechnology Ltd |
Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
|
|
WO2008063213A2
(fr)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
|
|
WO2007120626A2
(fr)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
|
|
CN106434527A
(zh)
|
2006-04-14 |
2017-02-22 |
安斯泰来再生医药协会 |
血管瘤集落形成细胞
|
|
US8808707B1
(en)
|
2006-05-08 |
2014-08-19 |
Wyeth Llc |
Pneumococcal dosing regimen
|
|
CA2653661A1
(fr)
|
2006-05-31 |
2007-12-06 |
Astellas Pharma Inc. |
Anticorps d'osteopontine anti-humains humanises
|
|
US20100021451A1
(en)
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
|
JP2009539792A
(ja)
|
2006-06-08 |
2009-11-19 |
シュヴァルツ・ファーマ・アーゲー |
疼痛の医学的状態のための治療組合せ
|
|
TWI392670B
(zh)
|
2006-06-22 |
2013-04-11 |
Ucb Pharma Gmbh |
經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
|
|
GB0612928D0
(en)
|
2006-06-29 |
2006-08-09 |
Ucb Sa |
Biological products
|
|
MX2008016335A
(es)
|
2006-06-30 |
2009-01-21 |
Abbott Biotech Ltd |
Dispositivo automatico de inyeccion.
|
|
GB0613209D0
(en)
|
2006-07-03 |
2006-08-09 |
Ucb Sa |
Methods
|
|
AU2007279092B2
(en)
|
2006-07-24 |
2012-12-13 |
Ucb Pharma S.A. |
Substituted aniline derivatives
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
SG174013A1
(en)
|
2006-07-27 |
2011-09-29 |
Wyeth Corp |
High-cell density fed-batch fermentation process for producing recombinant protein
|
|
JPWO2008026781A1
(ja)
|
2006-08-31 |
2010-01-21 |
直人 奥 |
逆標的化脂質小胞体
|
|
US20100035863A1
(en)
|
2006-09-12 |
2010-02-11 |
Ucb Pharma, S.A. |
2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
|
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
|
AU2007294731B2
(en)
|
2006-09-13 |
2014-04-17 |
Abbvie Inc. |
Cell culture improvements
|
|
PT2078080E
(pt)
|
2006-09-27 |
2015-09-18 |
Coley Pharm Gmbh |
Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
|
|
GB0619291D0
(en)
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
|
US10068220B2
(en)
|
2006-10-11 |
2018-09-04 |
Visa International Service Association |
Systems and methods for brokered authentication express seller links
|
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
|
ES2442258T3
(es)
|
2006-10-27 |
2014-02-10 |
Abbvie Biotechnology Ltd |
Anticuerpos cristalinos anti-hTNF alfa
|
|
WO2008064830A1
(fr)
|
2006-11-27 |
2008-06-05 |
Ucb Pharma, S.A. |
Dérivés bicycliques et hétérobicycliques, leurs procédés de fabrication et leurs utilisations pharmaceutiques
|
|
WO2008064823A1
(fr)
|
2006-11-27 |
2008-06-05 |
Ucb Pharma, S.A. |
Dérivés bicycliques et hétérobicycliques, procédés de préparation de ceux-ci et leurs utilisations
|
|
WO2008064829A2
(fr)
|
2006-11-30 |
2008-06-05 |
Ucb Pharma, S.A. |
Nouveaux dérivés d'aminothiénopyridinone, procédés de préparation de ces dérivés et compositions pharmaceutiques à base de ceux-ci
|
|
WO2008074445A1
(fr)
|
2006-12-18 |
2008-06-26 |
Ucb Pharma, S.A. |
Nouveaux dérivés tricycliques et hétérocycliques, procédés destinés à les préparer et compositions pharmaceutiques les contenant
|
|
MX2009007139A
(es)
|
2006-12-28 |
2009-10-08 |
Centocor Ortho Biotech Inc |
Metodos y vectores para generar inmunoglobulinas no sialiladas.
|
|
WO2008092084A2
(fr)
|
2007-01-26 |
2008-07-31 |
Centocor, Inc. |
Suspension non aqueuse injectable présentant une concentration élevée en agent thérapeutique
|
|
US8796021B2
(en)
|
2007-02-23 |
2014-08-05 |
Advanced Cell Technology, Inc. |
Blastomere culture to produce mammalian embryonic stem cells
|
|
US8147833B2
(en)
|
2007-02-23 |
2012-04-03 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
|
ME00832B
(fr)
|
2007-03-22 |
2012-03-20 |
Ucb Biopharma Sprl |
Protéines de liaison, incluant des anticorps, dérivés d'anticorps et fragments d'anticorps, qui se lient spécifiquement à cd154 et leurs utilisations
|
|
NZ580378A
(en)
|
2007-03-30 |
2012-11-30 |
Abbott Lab |
Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
|
|
WO2008122378A1
(fr)
|
2007-04-04 |
2008-10-16 |
Ucb Pharma, S.A. |
Nouveaux derives de pyridine, procedes de preparation et compositions pharmaceutiques associes
|
|
WO2008125210A1
(fr)
|
2007-04-12 |
2008-10-23 |
Ucb Pharma, S.A. |
Dérivés de quinoline et de naphtalène, procédés de préparation et utilisation de ceux-ci pour traiter des maladies inflammatoires
|
|
WO2008125215A1
(fr)
|
2007-04-12 |
2008-10-23 |
Ucb Pharma, S.A. |
Dérivés bicycliques et hétérobicycliques, procédés de préparation et utilisations de ceux-ci
|
|
TW200904421A
(en)
|
2007-05-03 |
2009-02-01 |
Astellas Pharma Inc |
New compounds
|
|
WO2008138591A2
(fr)
|
2007-05-14 |
2008-11-20 |
Ucb Pharma, S.A. |
Dérivés bicycliques et hétérobicycliques, leurs méthodes de préparation et leurs utilisations
|
|
WO2008138592A1
(fr)
|
2007-05-14 |
2008-11-20 |
Ucb Pharma, S.A. |
Dérivés bicycliques et hétérobicycliques, leurs méthodes de préparation et leurs utilisations
|
|
WO2008138615A1
(fr)
|
2007-05-16 |
2008-11-20 |
Ucb Pharma, S.A. |
Dérivés bicycliques et hétérobicycliques, leurs méthodes de préparation et leurs utilisations
|
|
EP1997832A1
(fr)
|
2007-05-29 |
2008-12-03 |
Ganymed Pharmaceuticals AG |
Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
|
|
WO2008150491A2
(fr)
|
2007-05-31 |
2008-12-11 |
Abbott Laboratories |
Biomarqueurs prédictifs de la réactivité aux inhibiteurs tnfα dans des troubles auto-immuns
|
|
US20100179137A1
(en)
|
2007-06-07 |
2010-07-15 |
Takashi Kamikubo |
Pyridone compound
|
|
US20100303813A1
(en)
|
2007-06-08 |
2010-12-02 |
Biogen Idec Ma Inc. |
Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
|
|
WO2008154543A2
(fr)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Procédés de traitement de l'arthrite idiopathique juvénile
|
|
WO2009020654A1
(fr)
|
2007-08-08 |
2009-02-12 |
Abbott Laboratories |
Compositions et procédés permettant la cristallisation d'anticorps
|
|
US8969024B2
(en)
|
2007-08-28 |
2015-03-03 |
Abbvie Biotechnology Ltd |
Compositions and methods comprising binding proteins for adalimumab
|
|
EP2535349A1
(fr)
|
2007-09-26 |
2012-12-19 |
UCB Pharma S.A. |
Fusions d'anticorps à double spécificité
|
|
US20100298289A1
(en)
|
2007-10-09 |
2010-11-25 |
Ucb Pharma, S.A. |
Heterobicyclic compounds as histamine h4-receptor antagonists
|
|
DK2209888T3
(da)
|
2007-10-12 |
2020-01-20 |
Astellas Inst For Regenerative Medicine |
Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
|
|
US7947495B2
(en)
|
2007-11-01 |
2011-05-24 |
Abbott Biotherapeutics Corp. |
Immunoglobulin display vectors
|
|
EP2612867A1
(fr)
|
2007-11-01 |
2013-07-10 |
Perseid Therapeutics LLC |
Acides nucléiques et polypeptides immunosuppresseurs
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
US8420081B2
(en)
|
2007-11-30 |
2013-04-16 |
Abbvie, Inc. |
Antibody formulations and methods of making same
|
|
PT2594590E
(pt)
|
2007-12-14 |
2015-01-14 |
Bristol Myers Squibb Co |
Moléculas de ligação ao recetor humano ox40
|
|
TWI478937B
(zh)
|
2008-01-15 |
2015-04-01 |
Abbvie Inc |
改良之哺乳動物表現載體及其用途
|
|
EA018462B1
(ru)
|
2008-01-25 |
2013-08-30 |
ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК МОДУЛЯТОРЫ СИНТЕЗА TNF-α И КАК ИНГИБИТОРЫ PDE4
|
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
|
CA3186451A1
(fr)
|
2008-05-06 |
2009-11-12 |
Astellas Institute For Regenerative Medicine |
Cellules formant des colonies hemangioblastiques et cellules hemangioblastiques non transplantables
|
|
US20110086424A1
(en)
|
2008-05-06 |
2011-04-14 |
Advanced Cell Technology, Inc. |
Methods for producing enucleated erythroid cells derived from pluripotent stem cells
|
|
EP2565191B1
(fr)
|
2008-05-14 |
2014-10-08 |
Astellas Pharma Inc. |
Dérivés d'acide 4-(indol-7-ylcarbonylaminométhyl)cyclohexanecarboxylique comme antagonistes du récepteur EP4 utilisables pour le traitement de l'insuffisance rénale chronique ou de la néphropathie diabétique
|
|
BRPI0909866B1
(pt)
|
2008-06-11 |
2021-08-24 |
Fresenius Medical Care Deutschland Gmbh |
Método de produção de um meio condicionado de células progenitoras de fígado, meio condicionado e composição farmacêutica
|
|
MX2010014231A
(es)
|
2008-06-17 |
2011-03-21 |
Astellas Pharma Inc |
Compuestos de piridona.
|
|
ES2569907T3
(es)
|
2008-06-27 |
2016-05-13 |
Zoetis Services Llc |
Composiciones adyuvantes novedosas
|
|
SMT201900652T1
(it)
|
2008-07-18 |
2020-01-14 |
Ucb Biopharma Sprl |
Sistemi per somministrare medicinale per pazienti con artrite reumatoide
|
|
EP2166021A1
(fr)
|
2008-09-16 |
2010-03-24 |
Ganymed Pharmaceuticals AG |
Anticorps monoclonaux pour le traitement du cancer
|
|
CA2737241C
(fr)
|
2008-09-26 |
2017-08-29 |
Ucb Pharma S.A. |
Proteines de fusion d'anticorps multivalentes
|
|
NZ592095A
(en)
|
2008-10-20 |
2013-01-25 |
Abbott Lab |
Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
|
|
BRPI0920572A8
(pt)
|
2008-10-20 |
2015-10-27 |
Abbott Lab |
Inativação viral durante a purificação dos anticorpos
|
|
CN104357381A
(zh)
|
2008-10-31 |
2015-02-18 |
辛西斯有限责任公司 |
用于活化干细胞的方法和装置
|
|
EP2358360B1
(fr)
|
2008-11-18 |
2016-09-14 |
UCB Biopharma SPRL |
Formules à libération prolongée comprenant un dérivé de 2-oxo-1-pyrrolidine
|
|
EP2327299B8
(fr)
|
2008-12-16 |
2012-06-27 |
Astellas Pharma Inc. |
Rongeur modèle de douleur musculaire chronique
|
|
NZ594315A
(en)
|
2009-02-17 |
2013-05-31 |
Ucb Pharma Sa |
Antibody molecules having specificity for human ox40
|
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
|
EP2414386B1
(fr)
|
2009-04-03 |
2016-01-27 |
Merial Limited |
Vaccins aviaires transportés par le virus de la maladie de newcastle
|
|
PE20120835A1
(es)
|
2009-04-16 |
2012-07-23 |
Abbvie Biotherapeutics Inc |
Anticuerpos anti-tnf-alfa y sus usos
|
|
WO2010127146A1
(fr)
|
2009-04-29 |
2010-11-04 |
Abbott Biotechnology Ltd |
Dispositif d'injection automatique
|
|
JP2012197228A
(ja)
|
2009-07-27 |
2012-10-18 |
Kyoto Univ |
肝炎の治療剤もしくは予防剤
|
|
WO2011030107A1
(fr)
|
2009-09-10 |
2011-03-17 |
Ucb Pharma S.A. |
Anticorps multivalents
|
|
US20110070227A1
(en)
|
2009-09-18 |
2011-03-24 |
Anna-Marie Novotney-Barry |
Treatment of Autoimmune and Inflammatory Diseases
|
|
WO2011036455A1
(fr)
|
2009-09-24 |
2011-03-31 |
Ucb Pharma S.A. |
Souche bactérienne pour l'expression de protéines recombinantes, ayant une degp à activité protéase déficiente et conservant une activité chaperonne et des gènes tsp et ptr inactivés
|
|
US9109216B2
(en)
|
2009-09-24 |
2015-08-18 |
Ucb Pharma, S.A. |
Bacterial host strain
|
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
JP2012254939A
(ja)
|
2009-10-07 |
2012-12-27 |
Astellas Pharma Inc |
オキサゾール化合物
|
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
|
IL281453B
(en)
|
2009-11-17 |
2022-07-01 |
Astellas Inst For Regenerative Medicine |
Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
|
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
|
US9096879B2
(en)
|
2009-11-24 |
2015-08-04 |
Biogen Ma Inc. |
Method of supplementing culture media to prevent undesirable amino acid substitutions
|
|
EP2510949A4
(fr)
|
2009-12-11 |
2013-11-13 |
Astellas Pharma Inc |
Agent thérapeutique pour la fibromyalgie
|
|
RU2582401C2
(ru)
|
2009-12-15 |
2016-04-27 |
Эббви Байотекнолоджи Лтд |
Усовершенствованная пусковая кнопка для автоматического инъекционного устройства
|
|
ES2674275T3
(es)
|
2009-12-17 |
2018-06-28 |
Centrexion Therapeutics Corporation |
Antagonistas del receptor CCR2 y usos de los mismos
|
|
LT3257504T
(lt)
|
2009-12-22 |
2024-08-26 |
UCB Biopharma SRL |
Polivinilpirolidonas, skirtas nekristalinės formos kietos rotigotino dispersijos stabilizavimui
|
|
RU2581020C2
(ru)
|
2009-12-22 |
2016-04-10 |
Селлдекс Терапьютикс, Инк. |
Композиции вакцин
|
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
GB201000590D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial host strain
|
|
GB201000587D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial hoist strain
|
|
GB201000588D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial host strain
|
|
GB201000591D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial hoist strain
|
|
GB201001791D0
(en)
|
2010-02-03 |
2010-03-24 |
Ucb Pharma Sa |
Process for obtaining antibodies
|
|
EP2545078A1
(fr)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Anticorps pd-1
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
EP2371864A1
(fr)
|
2010-03-23 |
2011-10-05 |
Ganymed Pharmaceuticals AG |
Anticorps monoclonaux pour le traitement du cancer
|
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
ES2717883T3
(es)
|
2010-03-25 |
2019-06-26 |
Ucb Biopharma Sprl |
Moléculas de DVD-LG estabilizadas con disulfuro
|
|
HUE049849T2
(hu)
|
2010-03-31 |
2020-10-28 |
Boehringer Ingelheim Int |
Anti-CD40 antitestek
|
|
KR20130010123A
(ko)
|
2010-04-07 |
2013-01-25 |
아비에 인코포레이티드 |
ＴＮＦ-α 결합 단백질
|
|
WO2011129382A1
(fr)
|
2010-04-16 |
2011-10-20 |
Abbott Japan Co. Ltd. |
Procédés et réactifs pour diagnostiquer la polyarthrite rhumatoïde
|
|
JP5809242B2
(ja)
|
2010-04-21 |
2015-11-10 |
アッヴィ バイオテクノロジー リミテッド |
治療薬の制御送達のための装着型自動注入装置
|
|
HRP20190047T1
(hr)
|
2010-05-04 |
2019-02-22 |
Five Prime Therapeutics, Inc. |
Protutijela koja se vežu na csf1r
|
|
WO2011146394A1
(fr)
|
2010-05-17 |
2011-11-24 |
Millipore Corporation |
Polymères répondant à des stimuli pour la purification de biomolécules
|
|
EP2575878B1
(fr)
|
2010-05-28 |
2018-06-13 |
Zoetis Belgium S.A. |
Vaccins comprenants cholestérole et cpg comme seules molécules adjuvantes-porteuses
|
|
EP2575884B1
(fr)
|
2010-06-03 |
2018-07-18 |
AbbVie Biotechnology Ltd |
Utilisations et compositions pour le traitement de l'hidrosadénite (hs)
|
|
WO2011158044A2
(fr)
|
2010-06-17 |
2011-12-22 |
Respivert Limited |
Formulations respiratoires et composés destinés à être utilisés dans ces formulations
|
|
EP2582391B1
(fr)
|
2010-06-18 |
2018-10-03 |
XBiotech, Inc |
Traitement de l'arthrite
|
|
WO2012012803A2
(fr)
|
2010-07-23 |
2012-01-26 |
Advanced Cell Technology, Inc. |
Procédés de détection de sous-populations rares de cellules et compositions de cellules très purifiées
|
|
GB201012599D0
(en)
|
2010-07-27 |
2010-09-08 |
Ucb Pharma Sa |
Process for purifying proteins
|
|
GB201012603D0
(en)
|
2010-07-27 |
2010-09-08 |
Ucb Pharma Sa |
Protein purification
|
|
GB201012784D0
(en)
|
2010-07-29 |
2010-09-15 |
Ucb Pharma Sa |
Method
|
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
|
AU2011300409B2
(en)
|
2010-09-10 |
2015-03-26 |
Wyeth Llc |
Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
|
|
JP2013249256A
(ja)
|
2010-09-15 |
2013-12-12 |
Astellas Pharma Inc |
脂肪性肝疾患治療薬
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
KR101920250B1
(ko)
|
2010-10-13 |
2018-11-20 |
얀센 바이오테크 인코포레이티드 |
인간 온코스타틴 m 항체 및 이용 방법
|
|
MX2019000046A
(es)
|
2010-11-04 |
2023-10-05 |
Boehringer Ingelheim Int |
Anticuerpos anti-il-23.
|
|
US8821865B2
(en)
|
2010-11-11 |
2014-09-02 |
Abbvie Biotechnology Ltd. |
High concentration anti-TNFα antibody liquid formulations
|
|
MX2013005974A
(es)
|
2010-12-02 |
2013-07-29 |
Ucb Pharma Gmbh |
Formulacion de lacosamida de administracion una vez al dia.
|
|
AR084210A1
(es)
|
2010-12-08 |
2013-05-02 |
Abbott Lab |
PROTEINAS DE UNION AL TNF-a
|
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
|
ME02734B
(fr)
|
2011-01-14 |
2017-10-20 |
Ucb Biopharma Sprl |
Molécules d'anticorps se liant à il-17a et il-17f
|
|
RU2727040C2
(ru)
|
2011-01-24 |
2020-07-17 |
Эббви Байотекнолоджи Лтд. |
Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
|
|
EP2686671A4
(fr)
|
2011-03-12 |
2015-06-24 |
Momenta Pharmaceuticals Inc |
N-glycanes contenant de la n-acétylhexosamine dans des produits de glycoprotéines
|
|
TW201249867A
(en)
|
2011-04-01 |
2012-12-16 |
Astellas Pharma Inc |
Novel anti-human il-23 receptor antibody
|
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
CA2837582C
(fr)
|
2011-05-27 |
2021-03-02 |
Merial Limited |
Vaccins genetiques contre le virus hendra et le virus nipah
|
|
EP2714162B1
(fr)
|
2011-05-27 |
2020-01-01 |
Boehringer Ingelheim International GmbH |
Inhalateur et capsule pour inhalateur
|
|
WO2012164390A2
(fr)
|
2011-06-02 |
2012-12-06 |
Ucb Pharma S.A. |
Auto-injecteur
|
|
UY34105A
(es)
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
|
CN103717729B
(zh)
|
2011-07-08 |
2017-11-21 |
动量制药公司 |
细胞培养方法
|
|
CN103827134A
(zh)
|
2011-07-20 |
2014-05-28 |
泽普泰恩股份有限公司 |
多肽分离方法
|
|
MX350096B
(es)
|
2011-08-12 |
2017-08-25 |
Merial Inc |
Preservación asistida con vacío de productos biológicos, en particular de vacunas.
|
|
US9802954B2
(en)
|
2011-08-24 |
2017-10-31 |
Boehringer Ingelheim International Gmbh |
Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
|
|
RS58146B1
(sr)
|
2011-09-08 |
2019-02-28 |
Univ New York |
Onkolitički herpes simpleks virus i njegova terapeutska upotreba
|
|
CN104080498B
(zh)
|
2011-09-22 |
2016-08-24 |
艾伯维公司 |
自动注射装置
|
|
CN108404127B
(zh)
|
2011-09-23 |
2025-12-12 |
埃克斯生物科技公司 |
恶病质治疗
|
|
EP2578582A1
(fr)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napthtalèn-1-yl) urées comme inhibiteurs de la p38 MAP kinase
|
|
KR101995274B1
(ko)
|
2011-10-03 |
2019-07-02 |
레스피버트 리미티드 |
P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아
|
|
US10485869B2
(en)
|
2011-10-18 |
2019-11-26 |
Coherus Biosciences, Inc. |
Etanercept formulations stabilized with meglumine
|
|
BR112014009146A8
(pt)
|
2011-10-18 |
2017-06-20 |
Coherus Biosciences Inc |
formulações de etanercepte estabilizadas com aminoácidos
|
|
PE20141545A1
(es)
|
2011-10-24 |
2014-11-26 |
Abbvie Inc |
Inmunoenlazadores dirigidos contra el tnf
|
|
EP2773439A4
(fr)
|
2011-10-31 |
2015-07-01 |
Merck Sharp & Dohme |
Procédé de chromatographie permettant de décomposer des agrégats d'anticorps hétérogènes
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
WO2013068571A1
(fr)
|
2011-11-11 |
2013-05-16 |
Ucb Pharma S.A. |
Anticorps se liant à l'albumine et leurs fragments de liaison
|
|
IL287381B2
(en)
|
2011-11-14 |
2024-04-01 |
Astellas Inst For Regenerative Medicine |
Pharmaceutical preparations of human rpe cells and uses thereof
|
|
SI2785359T1
(sl)
|
2011-11-30 |
2018-11-30 |
Astellas Institute For Regenerative Medicine |
Mezenhimske stromalne celice in uporabe povezane z njimi
|
|
US8961956B2
(en)
|
2011-11-30 |
2015-02-24 |
Ocata Therapeutics, Inc. |
Mesenchymal stromal cells and uses related thereto
|
|
DE102011087676A1
(de)
|
2011-12-02 |
2013-06-06 |
Continental Automotive Gmbh |
Verfahren und Vorrichtung zur Überprüfung einer Lautsprecheranordnung
|
|
US20130158077A1
(en)
|
2011-12-19 |
2013-06-20 |
Ares Trading S.A. |
Pharmaceutical compositions
|
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
WO2013129454A1
(fr)
|
2012-02-28 |
2013-09-06 |
アステラス製薬株式会社 |
Nouvel anticorps anti-récepteur il-23 humain
|
|
AU2013204609B2
(en)
|
2012-03-02 |
2015-10-01 |
Abbvie Inc. |
Automatic injection training device
|
|
JP2015509526A
(ja)
|
2012-03-07 |
2015-03-30 |
カディラ ヘルスケア リミティド |
医薬製剤
|
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
|
NZ629697A
(en)
|
2012-03-15 |
2017-01-27 |
Janssen Biotech Inc |
Human anti-cd27 antibodies, methods and uses
|
|
MY169061A
(en)
|
2012-03-22 |
2019-02-12 |
Merial Inc |
Modified marek's disease virus, and vaccines made therefrom
|
|
WO2013158273A1
(fr)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Procédés de modulation de la distribution de variant de lysine c-terminal
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
WO2013158279A1
(fr)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Procédés de purification de protéines pour réduire des espèces acides
|
|
AU2013255103B2
(en)
|
2012-05-02 |
2016-09-29 |
Syntara Limited |
Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
|
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
GB201208367D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Biological product
|
|
WO2013174403A1
(fr)
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
|
|
WO2013176754A1
(fr)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
|
|
BR112014030940B1
(pt)
|
2012-06-11 |
2022-09-06 |
UCB Biopharma SRL |
Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
|
|
WO2013186230A1
(fr)
|
2012-06-12 |
2013-12-19 |
Boehringer Ingelheim International Gmbh |
Formulation pharmaceutique destinée à un anticorps thérapeutique
|
|
EA201590061A1
(ru)
|
2012-06-21 |
2015-05-29 |
Юсб Фарма С.А. |
Фармацевтическая композиция
|
|
GB201212513D0
(en)
|
2012-07-13 |
2012-08-29 |
Ucb Pharma Sa |
Therapeutic agents
|
|
CN104619709B
(zh)
|
2012-07-13 |
2016-11-09 |
Ucb生物制药私人有限公司 |
作为tnf活性调节剂的咪唑并吡啶衍生物
|
|
JP2015180606A
(ja)
|
2012-08-01 |
2015-10-15 |
アステラス製薬株式会社 |
抗癌剤の併用による癌治療方法
|
|
WO2014020171A1
(fr)
|
2012-08-03 |
2014-02-06 |
Boehringer Ingelheim International Gmbh |
Capacité tampon d'anticorps
|
|
SG11201500499TA
(en)
|
2012-08-10 |
2015-03-30 |
Boehringer Ingelheim Int |
Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
HK1211981A1
(en)
|
2012-09-02 |
2016-06-03 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
|
PE20150964A1
(es)
|
2012-09-07 |
2015-07-25 |
Coherus Biosciences Inc |
Formulaciones acuosas estables de adalimumab
|
|
SI2895188T1
(en)
|
2012-09-11 |
2018-05-31 |
Coherus Biosciences, Inc. |
CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
|
|
KR20150056788A
(ko)
|
2012-09-19 |
2015-05-27 |
애브비 바이오테라퓨틱스 인크. |
면역원성이 감소된 항체의 동정 방법
|
|
BR122016023101B1
(pt)
|
2012-10-21 |
2022-03-22 |
Pfizer Inc |
Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
|
|
KR101668574B1
(ko)
|
2012-11-02 |
2016-10-24 |
화이자 인코포레이티드 |
브루톤 티로신 키나제 억제제
|
|
RS55593B1
(sr)
|
2012-11-13 |
2017-06-30 |
Array Biopharma Inc |
Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola
|
|
WO2014075697A1
(fr)
|
2012-11-13 |
2014-05-22 |
Biontech Ag |
Agents de traitement de maladies cancéreuses exprimant claudine
|
|
US9844594B2
(en)
|
2012-12-18 |
2017-12-19 |
Merck Sharp & Dohme Corp. |
Liquid formulations for an anti-TNF α antibody
|
|
US9926341B2
(en)
|
2012-12-20 |
2018-03-27 |
Merck Patent Gmbh |
Copolymers for protein precipitation
|
|
JP6502262B2
(ja)
|
2012-12-20 |
2019-04-17 |
ファイザー・インク |
糖複合化方法
|
|
CA2896053A1
(fr)
|
2012-12-21 |
2014-06-26 |
Ocata Therapeutics, Inc. |
Procedes de production de plaquettes a partir de cellules souches pluripotentes, et compositions associees
|
|
GB201223276D0
(en)
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
|
EP2938323A2
(fr)
|
2012-12-28 |
2015-11-04 |
Abbott Cardiovascular Systems, Inc. |
Compositions thérapeutiques contenant d'anticorps
|
|
EP2752426A1
(fr)
|
2013-01-03 |
2014-07-09 |
Covagen AG |
Composés de liaison d'albumine de sérum humain et leurs protéines de fusion
|
|
GB201300683D0
(en)
|
2013-01-15 |
2013-02-27 |
Apitope Int Nv |
Peptide
|
|
JP2016093104A
(ja)
|
2013-02-19 |
2016-05-26 |
国立大学法人京都大学 |
抗ヒトＣＤ３ε抗体又はそのフラグメント、及びそれを有効成分とする免疫抑制剤
|
|
US10493104B2
(en)
|
2013-02-20 |
2019-12-03 |
Samsung Life Public Welfare Foundation |
Composition for treating inflammatory brain diseases which includes stem cell as active ingredient
|
|
WO2014127785A1
(fr)
|
2013-02-20 |
2014-08-28 |
Ganymed Pharmaceuticals Ag |
Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
|
|
HK1207960A1
(en)
|
2013-03-12 |
2016-02-19 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
|
WO2014159579A1
(fr)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
|
|
ES2845473T3
(es)
|
2013-03-14 |
2021-07-26 |
Boehringer Ingelheim Int |
(Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
US9217168B2
(en)
|
2013-03-14 |
2015-12-22 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
|
MX366910B
(es)
|
2013-03-15 |
2019-07-30 |
Janssen Biotech Inc |
Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
|
|
JP6592426B2
(ja)
|
2013-03-15 |
2019-10-16 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
|
|
EP4292600A3
(fr)
|
2013-03-15 |
2024-04-10 |
Astellas Institute for Regenerative Medicine |
Photorécepteurs et progéniteurs de photorécepteurs produits à partir de cellules souches pluripotentes
|
|
WO2014146672A1
(fr)
|
2013-03-18 |
2014-09-25 |
Ganymed Pharmaceuticals Ag |
Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
|
|
SG10201708048XA
(en)
|
2013-03-18 |
2017-10-30 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
JP2016000003A
(ja)
|
2013-04-19 |
2016-01-07 |
アステラス製薬株式会社 |
新規抗ヒトｔｗｅａｋ抗体
|
|
JP6616284B2
(ja)
|
2013-04-23 |
2019-12-04 |
ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン |
特異的結合分子の人工ライブラリー
|
|
WO2014175287A1
(fr)
|
2013-04-26 |
2014-10-30 |
国立大学法人 京都大学 |
Composition médicinale destinée à empêcher la formation et/ou l'expansion d'un anévrisme cérébral ou réduire un tel anévrisme
|
|
WO2014182658A1
(fr)
|
2013-05-06 |
2014-11-13 |
Abbvie Inc. |
Compositions pour culture cellulaire et procédés pour les utiliser
|
|
EP2803668A1
(fr)
|
2013-05-17 |
2014-11-19 |
Boehringer Ingelheim International Gmbh |
Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
|
|
JP2016519152A
(ja)
|
2013-05-22 |
2016-06-30 |
ユーシービー バイオファルマ エスピーアールエル |
治療用タンパク質を含む粒子を製造する方法
|
|
WO2014193821A1
(fr)
|
2013-05-28 |
2014-12-04 |
Momenta Pharmaceuticals, Inc. |
Compositions pharmaceutiques comprenant un pyrophosphate
|
|
TWI596107B
(zh)
|
2013-06-25 |
2017-08-21 |
卡地拉保健有限公司 |
單株抗體之新穎純化方法
|
|
US20160215319A1
(en)
|
2013-07-06 |
2016-07-28 |
Cadila Helthcare Limited |
Improved process for production of monoclonal antibodies
|
|
SG11201600067YA
(en)
|
2013-07-23 |
2016-02-26 |
Biocon Ltd |
Methods for controlling fucosylation levels in proteins
|
|
CN105745081B
(zh)
|
2013-07-28 |
2019-10-25 |
惠普工业印刷有限公司 |
介质支承装置
|
|
CA2919790C
(fr)
|
2013-08-02 |
2018-06-19 |
Pfizer Inc. |
Anticorps anti-cxcr4 et conjugues anticorps-medicaments
|
|
CA2919783C
(fr)
|
2013-08-02 |
2018-02-06 |
Pfizer Inc. |
Inhibiteurs d'heterobicycloaryl rorc2 et ses methodes d'utilisation
|
|
GB201313888D0
(en)
|
2013-08-02 |
2013-09-18 |
Consort Medical Plc |
Assembly for an autoinjector device
|
|
UA119328C2
(uk)
|
2013-08-09 |
2019-06-10 |
Астеллас Фарма Інк. |
Антитіло до тslp-рецептора людини
|
|
US20160237399A1
(en)
|
2015-02-18 |
2016-08-18 |
Biogen Ma Inc. |
Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
|
|
PL3036320T5
(pl)
|
2013-08-19 |
2024-06-10 |
Biogen Ma Inc. |
Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
|
|
US10076749B2
(en)
|
2013-08-23 |
2018-09-18 |
Boehringer Ingelheim Rcv Gmbh & Co Kg |
Microparticles for cell disruption and/or biomolecule recovery
|
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
|
US20160192626A1
(en)
|
2013-09-18 |
2016-07-07 |
Kyoto University |
Method For Creating Endometriotic Cells And Endometriosis Model Animal
|
|
HUE057005T2
(hu)
|
2013-09-25 |
2022-04-28 |
Bioverativ Therapeutics Inc |
Oszlopon történõ vírusinaktiváló eljárások
|
|
EP3057616B1
(fr)
|
2013-10-16 |
2020-03-11 |
Outlook Therapeutics, Inc. |
Formulations de tampon pour stabilité d'anticorps améliorée
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
US9683998B2
(en)
|
2013-11-13 |
2017-06-20 |
Pfizer Inc. |
Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
|
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
GB201321738D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
GB201321748D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321749D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321745D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321743D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321731D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
ES2750236T3
(es)
|
2013-12-09 |
2020-03-25 |
UCB Biopharma SRL |
Derivados heteroaromáticos bicíclicos condensados como moduladores de la actividad del TNF
|
|
GB201321740D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321736D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321744D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321732D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321737D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
GB201321728D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321746D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321733D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
BR112016012243A2
(pt)
|
2013-12-09 |
2017-08-08 |
Ucb Biopharma Sprl |
Derivados de imidazopiridina como moduladores de atividade de tnf
|
|
GB201321739D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321742D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321729D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321741D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321730D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321734D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
GB201321735D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
CN104707146B
(zh)
*
|
2013-12-16 |
2019-04-16 |
浙江海正药业股份有限公司 |
一种含有阿达木单抗的药物组合物
|
|
WO2015097536A2
(fr)
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anticorps et fragments anti-vista
|
|
CN109535254B
(zh)
|
2013-12-24 |
2022-06-24 |
安斯泰来制药株式会社 |
抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
|
|
EP3088517B1
(fr)
|
2013-12-26 |
2023-11-01 |
Mitsubishi Tanabe Pharma Corporation |
Anticorps monoclonal neutralisant humain anti-il-33
|
|
PL3096786T3
(pl)
|
2014-01-21 |
2021-11-08 |
Pfizer Inc. |
Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
|
|
EP3099351B1
(fr)
|
2014-01-27 |
2019-11-06 |
UCB Biopharma SPRL |
Auto-injecteur
|
|
AP2016009347A0
(en)
|
2014-01-29 |
2016-07-31 |
Neuropore Therapies Inc |
Heteroarly amides as inhibitors of protein aggregation
|
|
EA033604B1
(ru)
|
2014-01-31 |
2019-11-08 |
Boehringer Ingelheim Int |
Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
|
|
WO2015120056A1
(fr)
|
2014-02-04 |
2015-08-13 |
Biogen Ma Inc. |
Chromatographie par échange cationique utilisée dans le mode de fixation par écoulement pour enrichir les modifications post-traductionnelles
|
|
PT3357919T
(pt)
|
2014-02-14 |
2020-02-20 |
Respivert Ltd |
Compostos heterocíclicos aromáticos como compostos antiinflamatórios
|
|
USRE47493E1
(en)
|
2014-02-20 |
2019-07-09 |
Boehringer Ingelheim International Gmbh |
Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
|
|
RU2016134913A
(ru)
|
2014-02-28 |
2018-03-30 |
Астеллас Фарма Инк. |
Новое биспецифическое антитело, связывающееся с tlr2 человека и tlr4 человека
|
|
US9135573B1
(en)
|
2014-03-17 |
2015-09-15 |
Linkedin Corporation |
Estimating reputation scores in reputation systems
|
|
CA2942546C
(fr)
|
2014-03-17 |
2022-11-22 |
Mitsubishi Tanabe Pharma Corporation |
Conjugues anticorps-fynomer
|
|
AU2015233654B2
(en)
|
2014-03-19 |
2018-12-06 |
Boehringer Ingelheim International Gmbh |
Heteroaryl Syk inhibitors
|
|
TW201623277A
(zh)
|
2014-03-26 |
2016-07-01 |
安斯泰來製藥股份有限公司 |
醯胺化合物
|
|
WO2015151115A1
(fr)
|
2014-04-02 |
2015-10-08 |
Intas Pharmaceuticals Limited |
Composition pharmaceutique liquide d'adalimumab
|
|
DK3126330T3
(en)
|
2014-04-04 |
2019-04-23 |
Pfizer |
BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
|
|
CN106456813B
(zh)
|
2014-04-15 |
2020-06-30 |
勃林格殷格翰国际公司 |
在制造生物制品期间连续灭活病毒的方法、装置和系统
|
|
AU2015248807B2
(en)
|
2014-04-17 |
2021-07-22 |
Boehringer Ingelheim Rcv Gmbh & Co Kg |
Recombinant host cell for expressing proteins of interest
|
|
KR102092225B1
(ko)
|
2014-04-30 |
2020-03-23 |
주식회사 엘지화학 |
고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
|
|
ES2936810T3
(es)
|
2014-05-16 |
2023-03-22 |
Pfizer |
Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
|
|
EP2946767B1
(fr)
|
2014-05-23 |
2016-10-05 |
Ares Trading S.A. |
Composition pharmaceutique liquide
|
|
PT2946765T
(pt)
|
2014-05-23 |
2016-11-10 |
Ares Trading Sa |
Composição farmacêutica líquida
|
|
ES2572919T3
(es)
|
2014-05-23 |
2016-06-03 |
Ares Trading S.A. |
Composición farmacéutica líquida
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
ES2864079T3
(es)
|
2014-05-30 |
2021-10-13 |
Pfizer |
Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
|
|
KR20170018810A
(ko)
|
2014-06-10 |
2017-02-20 |
메이지 세이카 파루마 가부시키가이샤 |
안정한 아달리무맙 수성 제제
|
|
TN2016000529A1
(en)
|
2014-06-17 |
2018-04-04 |
Pfizer |
Substituted dihydroisoquinolinone compounds
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
EP3708679A1
(fr)
|
2014-07-24 |
2020-09-16 |
Boehringer Ingelheim International GmbH |
Biomarqueurs utiles dans le traitement de maladies liées à l'il-23a
|
|
MD20170011A2
(ro)
|
2014-08-06 |
2017-08-31 |
Pfizer Inc. |
Compuşi imidazopiridazinici
|
|
IL250404B
(en)
|
2014-08-06 |
2022-07-01 |
Astellas Pharma Inc |
Novel anti-human igbeta antibody
|
|
AR101479A1
(es)
|
2014-08-11 |
2016-12-21 |
Boehringer Ingelheim Int |
Derivados de 6-alquinil-piridina
|
|
NO2721710T3
(fr)
|
2014-08-21 |
2018-03-31 |
|
|
|
CA2960096A1
(fr)
|
2014-09-03 |
2016-03-10 |
Bavarian Nordic A/S |
Procedes et compositions pour augmenter des reponses immunitaires
|
|
US10435464B1
(en)
|
2014-09-05 |
2019-10-08 |
Coherus Biosciences, Inc. |
Methods for making recombinant proteins
|
|
EP3189135B1
(fr)
|
2014-09-05 |
2021-06-02 |
Astellas Institute for Regenerative Medicine |
Cellules ganglionnaires de la rétine et leurs progénitrices
|
|
EP3511331A1
(fr)
|
2014-09-12 |
2019-07-17 |
Boehringer Ingelheim International GmbH |
Inhibiteurs spirocycliques de la cathepsine c
|
|
EP3194972B1
(fr)
|
2014-09-17 |
2021-04-14 |
Merck Patent GmbH |
Méthode de traitement de maladies provoquées par des métastases osseuses, médicaments à cet effet, et méthode de prédiction du résultat clinique du traitement de maladies provoquées par des métastases osseuses
|
|
WO2016046150A1
(fr)
|
2014-09-25 |
2016-03-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Polythérapie avec des inhibiteurs de sglt2 et des agonistes de la dopamine utilisée pour la prévention des troubles métaboliques chez des équidés
|
|
MA40759A
(fr)
|
2014-09-26 |
2017-08-01 |
Pfizer |
Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
|
|
PE20170693A1
(es)
|
2014-10-03 |
2017-06-13 |
Ucb Biopharma Sprl |
Derivados de imidazol pentaciclicos fusionados
|
|
HUP1400510A1
(hu)
*
|
2014-10-28 |
2016-05-30 |
Richter Gedeon Nyrt |
Gyógyászati TNFalfa ellenes antitest készítmény
|
|
KR102265924B1
(ko)
|
2014-10-31 |
2021-06-15 |
삼성바이오에피스 주식회사 |
Pdk 불활성화에 의한 폴리펩타이드의 생산
|
|
CN107073022B
(zh)
|
2014-10-31 |
2020-12-29 |
弗雷森纽斯医疗护理德国有限责任公司 |
包含甜菊苷的药物组合物
|
|
BR112017009595A2
(pt)
|
2014-11-14 |
2017-12-19 |
Boehringer Ingelheim Int |
morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
|
|
WO2016089126A1
(fr)
|
2014-12-03 |
2016-06-09 |
사회복지법인 삼성생명공익재단 |
Anticorps dirigé contre la neuropiline 1 et son utilisation
|
|
KR20160068558A
(ko)
|
2014-12-05 |
2016-06-15 |
삼성바이오에피스 주식회사 |
마우스 cmv 프로모터를 포함하는 융합 폴리뉴클레오타이드 및 이를 이용한 목적 폴리펩타이드의 생산 방법
|
|
CA2970577A1
(fr)
|
2014-12-22 |
2016-06-30 |
Ares Trading S.A. |
Composition pharmaceutique liquide
|
|
CN107108691B
(zh)
|
2014-12-22 |
2021-06-29 |
Ucb生物制药私人有限公司 |
蛋白质制造方法
|
|
EP3237432B1
(fr)
|
2014-12-22 |
2023-09-06 |
UCB Biopharma SRL |
Fabrication et purification de protéines
|
|
EP3237000A1
(fr)
*
|
2014-12-23 |
2017-11-01 |
Pfizer Inc |
Formulation d'anticorps aqueuse stable pour des anticorps anti tnf alpha
|
|
WO2016118707A1
(fr)
|
2015-01-21 |
2016-07-28 |
Oncobiologics, Inc. |
Modulation de variants de charge dans une composition d'anticorps monoclonaux
|
|
US20180016333A1
(en)
*
|
2015-01-28 |
2018-01-18 |
Mabxience, S.A. |
Pharmaceutical formulations for anti-tnf-alpha antibodies
|
|
GB201501613D0
(en)
|
2015-01-30 |
2015-03-18 |
Ucb Biopharma Sprl |
Treatment of autoimmune disorders with CD154 antibodies
|
|
WO2016120849A1
(fr)
|
2015-01-30 |
2016-08-04 |
Pfizer Inc. |
Modulateurs de pyrrolopyridine substituée par un méthoxy de rorc2 et leurs méthodes d'utilisation
|
|
US10385036B2
(en)
|
2015-01-30 |
2019-08-20 |
Pfizer Inc. |
Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof
|
|
EP3053572A1
(fr)
|
2015-02-06 |
2016-08-10 |
Ares Trading S.A. |
Composition pharmaceutique liquide
|
|
SG11201706505PA
(en)
*
|
2015-02-13 |
2017-09-28 |
Sanofi Sa |
Stable liquid formulation for monoclonal antibodies
|
|
EP3268042B1
(fr)
|
2015-03-13 |
2024-11-27 |
Samsung Bioepis Co., Ltd. |
Composition contenant un polypeptide anti-tnf-alpha et utilisation
|
|
JP6744324B2
(ja)
|
2015-04-01 |
2020-08-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
細胞培養培地
|
|
WO2016162819A1
(fr)
*
|
2015-04-07 |
2016-10-13 |
Lupin Limited |
Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha
|
|
EP3078675A1
(fr)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
|
|
US10294304B2
(en)
|
2015-04-13 |
2019-05-21 |
Pfizer Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
KR20170135972A
(ko)
|
2015-04-14 |
2017-12-08 |
베링거 인겔하임 인터내셔날 게엠베하 |
질환을 치료하는 방법
|
|
WO2016165765A1
(fr)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer
|
|
EP3081227A1
(fr)
|
2015-04-15 |
2016-10-19 |
Institut National De La Recherche Agronomique |
Lactococcus lactis produisant du tslp ou il-25 et leurs utilisations comme probiotiques et thérapeutiques
|
|
GB201506786D0
(en)
|
2015-04-21 |
2015-06-03 |
Ucb Biopharma Sprl |
Therapeutic use
|
|
JP6680297B2
(ja)
|
2015-04-28 |
2020-04-15 |
アステラス製薬株式会社 |
経口投与用医薬組成物
|
|
US10287346B2
(en)
|
2015-04-28 |
2019-05-14 |
Mitsubishi Tanabe Pharma Corporation |
RGMa binding protein and use thereof
|
|
TW201702271A
(zh)
|
2015-04-30 |
2017-01-16 |
哈佛大學校長及研究員協會 |
治療代謝病症之抗－ａｐ２抗體及抗原結合劑
|
|
MY182282A
(en)
|
2015-05-04 |
2021-01-18 |
Pfizer |
Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
|
|
JP6851322B2
(ja)
|
2015-05-27 |
2021-03-31 |
ユーシービー バイオファルマ エスアールエル |
神経疾患を治療する方法
|
|
EP3303561A2
(fr)
|
2015-05-29 |
2018-04-11 |
Biogen MA Inc. |
Méthodes et systèmes de culture cellulaire
|
|
US10308615B2
(en)
|
2015-05-29 |
2019-06-04 |
Pfizer Inc. |
Heterocyclic compounds as inhibitors of Vanin-1 enzyme
|
|
GB201509885D0
(en)
|
2015-06-08 |
2015-07-22 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
GB201509888D0
(en)
|
2015-06-08 |
2015-07-22 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
GB201509893D0
(en)
|
2015-06-08 |
2015-07-22 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
CN107787322B
(zh)
|
2015-06-17 |
2023-07-07 |
辉瑞大药厂 |
三环化合物以及它们作为磷酸二酯酶抑制剂的用途
|
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
|
AR105025A1
(es)
|
2015-06-19 |
2017-08-30 |
Astellas Pharma Inc |
Compuesto de imidazodiazepina
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
EA034885B1
(ru)
|
2015-07-03 |
2020-04-02 |
Астеллас Фарма Юэроп Лтд. |
Новая схема лечения тиакумициновым соединением
|
|
US10344081B2
(en)
|
2015-07-06 |
2019-07-09 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
WO2017005734A1
(fr)
|
2015-07-06 |
2017-01-12 |
Ucb Biopharma Sprl |
Anticorps se liant à tau
|
|
KR102225282B1
(ko)
|
2015-07-21 |
2021-03-10 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
|
WO2017015433A2
(fr)
|
2015-07-23 |
2017-01-26 |
Boehringer Ingelheim International Gmbh |
Composé ciblant le facteur d'activation d'il-23 et des lymphocytes b (baff) et utilisations associées
|
|
EP3333165B1
(fr)
|
2015-08-04 |
2019-09-18 |
Astellas Pharma Inc. |
Dérivé de pipérazine
|
|
CN108697641A
(zh)
|
2015-08-18 |
2018-10-23 |
安斯泰来再生医药协会 |
临床制剂
|
|
HUE053705T2
(hu)
|
2015-08-27 |
2021-07-28 |
Pfizer |
Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként
|
|
CN107922501A
(zh)
|
2015-09-01 |
2018-04-17 |
勃林格殷格翰国际有限公司 |
抗cd40抗体用于治疗狼疮性肾炎的用途
|
|
HUE065661T2
(hu)
|
2015-09-29 |
2024-06-28 |
Boehringer Ingelheim Animal Health Usa Inc |
Kutya parvovírus (CPV) vírusszerû részecske (VLP) vakcinák és alkalmazásuk
|
|
BR112018006251A2
(pt)
|
2015-09-30 |
2018-10-16 |
Janssen Biotech Inc |
anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
|
|
DK3359688T3
(da)
|
2015-10-05 |
2021-08-23 |
Biogen Ma Inc |
Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme
|
|
KR101949451B1
(ko)
|
2015-10-13 |
2019-05-10 |
주식회사 이노파마스크린 |
염증성 장 질환 및 아토피 피부염 치료용 조성물
|
|
US10208024B2
(en)
|
2015-10-23 |
2019-02-19 |
Array Biopharma Inc. |
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
|
|
CN116059350A
(zh)
|
2015-10-27 |
2023-05-05 |
Ucb生物制药有限责任公司 |
使用抗-il-17a/f抗体的治疗方法
|
|
EA201891084A1
(ru)
|
2015-11-02 |
2019-10-31 |
|
Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
|
|
EP3371150B1
(fr)
|
2015-11-03 |
2021-08-18 |
UCB Biopharma SRL |
Procede de preperation de brivaracetam
|
|
DK3380119T3
(da)
|
2015-11-23 |
2021-11-15 |
Boehringer Ingelheim Animal Health Usa Inc |
Fmdv- og e2-fusionsproteiner og anvendelser deraf
|
|
TWI812873B
(zh)
|
2015-11-30 |
2023-08-21 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
LT3390390T
(lt)
|
2015-12-16 |
2021-11-25 |
Boehringer Ingelheim International Gmbh |
Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
|
|
GB201522391D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibody molecules
|
|
SG10202012778YA
(en)
|
2015-12-18 |
2021-01-28 |
Astellas Pharma Inc |
Pharmaceutical composition comprising anti-human tslp receptor antibody
|
|
US10570118B2
(en)
|
2016-01-13 |
2020-02-25 |
Boehringer Ingelheim International Gmbh |
Isoquinolones as BTK inhibitors
|
|
MX2018008771A
(es)
|
2016-01-19 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Formulaciones/composiciones que comprenden un inhibidor de btk.
|
|
MX2018008797A
(es)
|
2016-01-19 |
2018-11-29 |
Pfizer |
Vacunas contra el cancer.
|
|
US20190290650A1
(en)
|
2016-01-19 |
2019-09-26 |
Janssen Pharmaceutic Nv |
Formulations/compositions comprising a btk inhibitor
|
|
CN109219618B
(zh)
|
2016-01-21 |
2022-08-09 |
辉瑞大药厂 |
针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
|
|
TWI755547B
(zh)
|
2016-01-21 |
2022-02-21 |
美商輝瑞股份有限公司 |
靶向表皮生長因子受體變異體iii之嵌合型抗原受體
|
|
MA46681A
(fr)
|
2016-01-28 |
2019-09-11 |
Janssen Biotech Inc |
Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
|
|
TWI760322B
(zh)
|
2016-01-29 |
2022-04-11 |
美商百靈佳殷格翰動物保健美國有限公司 |
重組腺病毒載體裝載之fmdv疫苗及其用途
|
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
|
EP3413915A1
(fr)
|
2016-02-08 |
2018-12-19 |
Synaffix B.V. |
Conjugués d'anticorps à indice thérapeutique amélioré permettant de cibler des tumeurs positives pour le her2 et méthode pour améliorer l'indice thérapeutique de conjugués d'anticorps
|
|
DE102016001407A1
(de)
|
2016-02-09 |
2017-08-24 |
Fresenius Medical Care Deutschland Gmbh |
Blutbehandlung mit Inaktivierung von freien Nukleinsäuren
|
|
GB201602938D0
(en)
|
2016-02-19 |
2016-04-06 |
Ucb Biopharma Sprl |
Protein purification
|
|
CN113332292A
(zh)
|
2016-02-23 |
2021-09-03 |
辉瑞公司 |
6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
|
|
GB201603104D0
(en)
|
2016-02-23 |
2016-04-06 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
CN109071546B
(zh)
|
2016-02-24 |
2021-03-02 |
辉瑞大药厂 |
作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
|
|
US10611800B2
(en)
|
2016-03-11 |
2020-04-07 |
Pfizer Inc. |
Human cytomegalovirus gB polypeptide
|
|
CN109311965B
(zh)
|
2016-03-11 |
2023-07-18 |
勃林格殷格翰国际公司 |
在制造蛋白质期间连续灭活病毒的方法
|
|
US10519479B1
(en)
|
2016-03-15 |
2019-12-31 |
Ares Trading S.A. |
Methods for modifying glycosylation using manganese
|
|
EP3431079B1
(fr)
|
2016-03-15 |
2023-06-07 |
Astellas Pharma Inc. |
Comprimé
|
|
US10526631B1
(en)
|
2016-03-15 |
2020-01-07 |
Ares Trading S.A. |
Method of reducing serine for asparagine misincorporation
|
|
KR102023058B1
(ko)
|
2016-03-25 |
2019-09-19 |
사회복지법인 삼성생명공익재단 |
이중 이온 pH-민감성 공중합체를 이용한 허혈성 뇌질환 치료용 약물 전달체
|
|
CA3018155A1
(fr)
|
2016-03-29 |
2017-10-05 |
Astellas Pharma Inc. |
Polytherapie pour le traitement de la leucemie myeloide aigue
|
|
MX2018011435A
(es)
|
2016-04-01 |
2019-01-10 |
Ucb Biopharma Sprl |
Metodo para purificacion de proteinas.
|
|
EP3436460B1
(fr)
|
2016-04-01 |
2021-08-18 |
UCB Biopharma SRL |
Dérivés d'imidazole pentacyclique condensé comme modulateurs de l'activité du tnf
|
|
JP6968092B2
(ja)
|
2016-04-01 |
2021-11-17 |
ユーシービー バイオファルマ エスアールエル |
Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
|
|
EA201892144A1
(ru)
|
2016-04-01 |
2019-04-30 |
Юсб Байофарма Спрл |
Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf
|
|
JP6968091B2
(ja)
|
2016-04-01 |
2021-11-17 |
ユーシービー バイオファルマ エスアールエル |
Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
|
|
EP3441065B1
(fr)
|
2016-04-06 |
2024-10-09 |
Astellas Pharma Inc. |
Moulage tridimensionnel à élution rapide, filament pour moulage tridimensionnel à élution rapide et matériau pour moulage tridimensionnel à élution rapide
|
|
EP3439690A2
(fr)
|
2016-04-07 |
2019-02-13 |
Merial, Inc. |
Vaccin contre le ver du c ur, procédés et utilisations associés
|
|
CN108884050B
(zh)
|
2016-04-13 |
2022-07-05 |
Ucb生物制药私人有限公司 |
四氢异喹啉衍生物
|
|
JP7250520B2
(ja)
|
2016-04-13 |
2023-04-03 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
組換えアルテリウイルスレプリコン系およびその使用
|
|
WO2017178586A1
(fr)
|
2016-04-15 |
2017-10-19 |
Cellectis |
Méthode de mise au point par génie génétique de lymphocytes t hypersensibles à un promédicament spécifique pour une immunothérapie par expression génique
|
|
KR20230119259A
(ko)
|
2016-04-15 |
2023-08-16 |
이뮤넥스트, 인크. |
항-인간 vista 항체 및 이의 용도
|
|
MX2018013038A
(es)
|
2016-04-27 |
2019-03-28 |
Pfizer |
Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
|
|
KR20170122650A
(ko)
|
2016-04-27 |
2017-11-06 |
사회복지법인 삼성생명공익재단 |
미숙아 뇌실내 출혈 치료를 위한 고효능 줄기세포 선별법
|
|
CA3022494A1
(fr)
|
2016-05-01 |
2017-11-09 |
Ucb Biopharma Sprl |
Domaine de liaison a une proteine porteuse serique, avec affinite genetiquement modifiee
|
|
EP3455363B1
(fr)
|
2016-05-10 |
2021-12-08 |
Ares Trading S.A. |
Procédés de modulation des profils de galactosylation de protéines recombinantes au moyen de galactose de peracétyle
|
|
GB201608323D0
(en)
|
2016-05-12 |
2016-06-29 |
Ucb Biopharma Sprl |
Pharmaceutical compositions
|
|
GB201608797D0
(en)
|
2016-05-19 |
2016-07-06 |
Ucb Biopharma Sprl |
Therapeutic use
|
|
US20190336552A1
(en)
|
2016-05-30 |
2019-11-07 |
Astellas Pharma Inc. |
Genetically engineered vaccinia viruses
|
|
TW201808987A
(zh)
|
2016-06-08 |
2018-03-16 |
健生生物科技公司 |
Ｇｍ－ｃｓｆ變體及使用方法
|
|
GB201610044D0
(en)
|
2016-06-08 |
2016-07-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
|
WO2018011681A1
(fr)
|
2016-07-14 |
2018-01-18 |
Pfizer Inc. |
Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1
|
|
EP3484507A1
(fr)
|
2016-07-15 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Méthodes et compositions permettant l'induction d'une immunité protectrice contre l'infection par le virus de marburg
|
|
WO2018016458A1
(fr)
|
2016-07-19 |
2018-01-25 |
アステラス製薬株式会社 |
Dérivé de pipérazine
|
|
WO2018022851A1
(fr)
|
2016-07-28 |
2018-02-01 |
Mitobridge, Inc. |
Méthode de traitement de lésions rénales aiguës.
|
|
US20190270778A1
(en)
|
2016-07-29 |
2019-09-05 |
Pfizer Inc. |
Cyclic Peptides As C5a Receptor Antagonists
|
|
JPWO2018030459A1
(ja)
|
2016-08-10 |
2019-06-13 |
アステラス製薬株式会社 |
膵がんでのｃｌｄｎ１８−ａｒｈｇａｐ６融合遺伝子又はｃｌｄｎ１８−ａｒｈｇａｐ２６融合遺伝子の検出
|
|
WO2018033482A1
(fr)
|
2016-08-17 |
2018-02-22 |
Boehringer Ingelheim International Gmbh |
Procédé de préparation de formulations liquides hautement concentrées contenant des biomolécules
|
|
US20190292265A1
(en)
|
2016-08-19 |
2019-09-26 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with an Anti-NKG2D Antibody
|
|
CA3034402A1
(fr)
|
2016-09-12 |
2018-03-15 |
Ares Trading S.A. |
Procedes pour la modulation de profils de production de proteines recombinantes
|
|
AU2017327539B2
(en)
|
2016-09-15 |
2020-12-24 |
Boehringer Ingelheim International Gmbh |
Heteroaryl carboxamide compounds as inhibitors of RIPK2
|
|
KR102546471B1
(ko)
|
2016-09-27 |
2023-06-21 |
프레제니우스 카비 도이치란트 게엠베하 |
액상의 약학 조성물
|
|
GB201616563D0
(en)
|
2016-09-29 |
2016-11-16 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
US10537590B2
(en)
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
|
ES3007557T3
(en)
|
2016-10-17 |
2025-03-20 |
Pfizer |
Anti-edb antibodies and antibody-drug conjugates
|
|
KR101971322B1
(ko)
|
2016-10-17 |
2019-04-23 |
사회복지법인 삼성생명공익재단 |
Ｓｏｃｓ의 발현 또는 활성 억제를 이용한 고효능 줄기세포 선별방법
|
|
KR101971323B1
(ko)
|
2016-10-17 |
2019-04-23 |
사회복지법인 삼성생명공익재단 |
면역질환 치료를 위한 고효능 줄기세포 선별방법
|
|
GB201617924D0
(en)
|
2016-10-24 |
2016-12-07 |
Ucb Biopharma Sprl |
Proteins and users
|
|
WO2018079570A1
(fr)
|
2016-10-26 |
2018-05-03 |
アステラス製薬株式会社 |
Composition pharmaceutique stable
|
|
KR101837449B1
(ko)
|
2016-10-28 |
2018-03-12 |
삼성전자주식회사 |
마이크로 니들 패치, 마이크로 니들을 제조하는 방법 및 장치
|
|
KR20190078572A
(ko)
|
2016-10-31 |
2019-07-04 |
프레제니우스 카비 도이치란트 게엠베하 |
액상의 약학 조성물
|
|
EA201991096A1
(ru)
|
2016-10-31 |
2019-09-30 |
Вектура Лимитед |
Ингалируемая порошковая композиция, содержащая анти-il-13-антитело
|
|
TWI780082B
(zh)
|
2016-11-18 |
2022-10-11 |
日商安斯泰來製藥股份有限公司 |
新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
|
|
US10949973B2
(en)
|
2016-11-23 |
2021-03-16 |
Wake Forest University Health Sciences |
Medical image analysis using mechanical deformation information
|
|
GB201620948D0
(en)
|
2016-12-09 |
2017-01-25 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
RU2754058C2
(ru)
|
2016-12-13 |
2021-08-26 |
Астеллас Фарма Инк. |
Антитело к cd73 человека
|
|
GB201621728D0
(en)
|
2016-12-20 |
2017-02-01 |
Ucb Biopharma Sprl |
Methods
|
|
WO2018119142A1
(fr)
|
2016-12-21 |
2018-06-28 |
Amgen Inc. |
Formulations d'anticorps anti-tnf alpha
|
|
TWI754702B
(zh)
|
2016-12-28 |
2022-02-11 |
德商Ｕｃｂ製藥有限公司 |
（氮雜）吲哚－和苯並呋喃－３－磺醯胺類
|
|
BR112019014833A2
(pt)
|
2017-01-20 |
2020-04-14 |
Pfizer |
composições imunogênicas para uso em vacinas pneumococais
|
|
WO2018138591A1
(fr)
|
2017-01-24 |
2018-08-02 |
Pfizer Inc. |
Dérivés de calichéamicine et conjugués anticorps-médicaments de ceux-ci
|
|
SI3575284T1
(sl)
|
2017-01-24 |
2021-11-30 |
Astellas Pharma Inc. |
Spojina fenildifluorometil substituiranega prolinamida
|
|
EA201991755A1
(ru)
|
2017-01-26 |
2020-01-22 |
Юсб Байофарма Спрл |
Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков
|
|
CN110198938B
(zh)
|
2017-01-26 |
2023-03-14 |
Ucb生物制药私人有限公司 |
作为蛋白质聚集调节剂的双-杂芳基衍生物
|
|
WO2018140121A1
(fr)
|
2017-01-30 |
2018-08-02 |
Janssen Biotech, Inc. |
Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
|
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
|
MX2019009377A
(es)
|
2017-02-07 |
2019-12-11 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
|
|
EP3582813A4
(fr)
|
2017-02-16 |
2020-12-30 |
XBiotech, Inc |
Traitement de l'hidradénite suppurative
|
|
JP7467119B2
(ja)
|
2017-02-17 |
2024-04-15 |
ロンザ リミテッド |
発現困難タンパク質のための多部位ｓｓｉ細胞
|
|
EP4417262A3
(fr)
|
2017-03-01 |
2024-11-27 |
Janssen Sciences Ireland Unlimited Company |
Polythérapie
|
|
EP3372242A1
(fr)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Composition pharmaceutique liquide
|
|
EP3372241A1
(fr)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Composition pharmaceutique liquide
|
|
WO2018163030A1
(fr)
|
2017-03-10 |
2018-09-13 |
Pfizer Inc. |
Dérivés d'imidazo [4,5-c] quinoléine substitués cycliques
|
|
WO2018167176A1
(fr)
|
2017-03-15 |
2018-09-20 |
Ucb Biopharma Sprl |
Dérivés d'imidazole pentacycliques condensés utilisés en tant que modulateurs de l'activité du tnf
|
|
JP6901292B2
(ja)
|
2017-03-15 |
2021-07-14 |
株式会社Adeka |
水溶性組成物、その硬化物の製造方法、およびその硬化物、並びにアシルホスフィン酸塩
|
|
JP2020514370A
(ja)
|
2017-03-17 |
2020-05-21 |
キュアバック アーゲー |
組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤
|
|
JOP20190218A1
(ar)
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
|
WO2018178250A1
(fr)
|
2017-03-31 |
2018-10-04 |
Boehringer Ingelheim International Gmbh |
Polythérapie anticancéreuse
|
|
CA3058980A1
(fr)
|
2017-04-25 |
2018-11-01 |
Ucb Biopharma Sprl |
Derives d'imidazole pentacycliques fusionnes utilises en tant que modulateurs de l'activite du tnf
|
|
WO2018200788A1
(fr)
|
2017-04-26 |
2018-11-01 |
Beryllium, Llc |
Agents de liaison d'oligonucléotides
|
|
KR20200014379A
(ko)
|
2017-06-05 |
2020-02-10 |
얀센 바이오테크 인코포레이티드 |
비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
|
|
AU2018285131B2
(en)
|
2017-06-12 |
2021-11-11 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds as Vanin inhibitors
|
|
GB201709456D0
(en)
|
2017-06-14 |
2017-07-26 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
EP3652211A1
(fr)
|
2017-07-14 |
2020-05-20 |
Pfizer Inc. |
Anticorps dirigés contre madcam
|
|
WO2019018647A1
(fr)
|
2017-07-20 |
2019-01-24 |
Pfizer Inc. |
Anticorps anti-gd3 et conjugués anticorps-médicament
|
|
CA3068779A1
(fr)
|
2017-08-11 |
2019-02-14 |
Boehringer Ingelheim International Gmbh |
Sites d'integration dans des cellules cho
|
|
WO2019035649A1
(fr)
|
2017-08-14 |
2019-02-21 |
주식회사 레고켐 바이오사이언스 |
Conjugués anticorps-médicament comprenant un anticorps contre egfrviii
|
|
WO2019034973A1
(fr)
|
2017-08-14 |
2019-02-21 |
Pfizer Inc. |
Pyrazolo[1,5-a]pyrazin-4-yl et dérivés associés
|
|
WO2019038338A1
(fr)
|
2017-08-23 |
2019-02-28 |
Sandoz Ag |
Système d'expression de protéines à multiples copies géniques
|
|
JP7250766B2
(ja)
|
2017-08-25 |
2023-04-03 |
ヤンセン バイオテツク，インコーポレーテツド |
ＦＣγＲＩＩ結合フィブロネクチンＩＩＩ型ドメイン、それらのコンジュゲート、及びそれらを含む多重特異性分子
|
|
JP2020531557A
(ja)
|
2017-08-30 |
2020-11-05 |
アレス トレーディング ソシエテ アノニム |
タンパク質の精製方法
|
|
IL272864B2
(en)
|
2017-08-31 |
2024-03-01 |
Mitsubishi Tanabe Pharma Corp |
Il-33 antagonist-containing therapeutic agent for endometriosis
|
|
CA3074865A1
(fr)
|
2017-09-14 |
2019-03-21 |
Icagen, Inc. |
Procedes de detection utilisant la fluorescence x
|
|
KR102188572B1
(ko)
|
2017-09-25 |
2020-12-09 |
사회복지법인 삼성생명공익재단 |
뇌척수액을 포함하는 줄기세포 투여 제형 및 그의 제조방법
|
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
|
|
CN111201243B
(zh)
|
2017-09-29 |
2023-08-11 |
财团法人牧岩生命科学研究所 |
对bcma具有高亲和力的抗bcma抗体和包含其的用于治疗癌症的药物组合物
|
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
|
US20190153096A1
(en)
|
2017-10-02 |
2019-05-23 |
Covagen Ag |
Cd3/cd33 bispecific binding molecules
|
|
US20190100587A1
(en)
|
2017-10-02 |
2019-04-04 |
Covagen Ag |
IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
|
|
WO2019073069A1
(fr)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
Anticorps humains dirigés contre l'antigène thomsen-nouveau (tn)
|
|
CA3078806A1
(fr)
|
2017-10-13 |
2019-04-18 |
Merck Patent Gmbh |
Combinaison d'un inhibiteur de parp et d'un antagoniste de liaison d'axe pd-1
|
|
US20200332251A1
(en)
|
2017-10-13 |
2020-10-22 |
Boehringer Ingelheim International Gmbh |
Perfusion medium
|
|
EP3697816A1
(fr)
|
2017-10-19 |
2020-08-26 |
Debiopharm International S.A. |
Produit de combinaison pour le traitement du cancer
|
|
MX2020004381A
(es)
|
2017-10-27 |
2020-08-20 |
Pfizer |
Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
|
|
JP2021502349A
(ja)
|
2017-11-06 |
2021-01-28 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
|
|
WO2019099970A1
(fr)
|
2017-11-20 |
2019-05-23 |
Janssen Pharmaceuticals Inc. |
Procédé d'administration sûre de vecteurs adénoviraux codant pour un antigène du virus zika
|
|
GB201719447D0
(en)
|
2017-11-23 |
2018-01-10 |
Ucb Biopharma Sprl |
Pharmaceutical composition
|
|
KR20190064293A
(ko)
|
2017-11-30 |
2019-06-10 |
(주)메디노 |
미숙아 뇌실내 출혈 치료를 위한 고효능 줄기세포 선별법
|
|
CN111615520A
(zh)
|
2017-12-01 |
2020-09-01 |
辉瑞大药厂 |
抗cxcr5抗体及其组合物和用途
|
|
GB201720970D0
(en)
|
2017-12-15 |
2018-01-31 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201720975D0
(en)
|
2017-12-15 |
2018-01-31 |
Ucb Biopharma Sprl |
Anti-alpha synuclein antibodies
|
|
TW201938165A
(zh)
|
2017-12-18 |
2019-10-01 |
美商輝瑞股份有限公司 |
治療癌症的方法及組合療法
|
|
EA202091516A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
|
|
KR20200100745A
(ko)
|
2017-12-19 |
2020-08-26 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물
|
|
AU2018392658B2
(en)
|
2017-12-20 |
2024-07-25 |
Ares Trading S.A. |
Methods for modulating protein mannosylation profiles using maduramycin, narasin, or salinomycin
|
|
US20210002371A1
(en)
|
2017-12-21 |
2021-01-07 |
Brian A. Sherer |
Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer
|
|
US11472794B2
(en)
|
2018-01-15 |
2022-10-18 |
UCB Biopharma SRL |
Fused imidazole derivatives as IL-17 modulators
|
|
CA3087481A1
(fr)
|
2018-01-15 |
2019-07-18 |
Pfizer Inc. |
Methodes d'administration d'immunotherapie par recepteur d'antigene chimerique en combinaison avec un agoniste de 4-1bb
|
|
CN112020518A
(zh)
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
靶向cd70的嵌合抗原受体
|
|
PE20210708A1
(es)
|
2018-02-01 |
2021-04-16 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos
|
|
TW202430218A
(zh)
|
2018-02-27 |
2024-08-01 |
美商輝瑞大藥廠 |
抗體純化
|
|
AU2019228381B2
(en)
|
2018-02-28 |
2021-12-16 |
Pfizer Inc. |
IL-15 variants and uses thereof
|
|
CN111819192A
(zh)
|
2018-03-02 |
2020-10-23 |
艾洛基治疗公司 |
可诱导的嵌合细胞激素受体
|
|
MX2020009265A
(es)
|
2018-03-05 |
2020-10-01 |
Janssen Biotech Inc |
Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
|
|
IL277095B2
(en)
|
2018-03-07 |
2025-10-01 |
Pfizer |
Preparations containing anti-PD-1 antibody
|
|
JP2021517577A
(ja)
|
2018-03-14 |
2021-07-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
炎症性腸疾患の処置のための抗ｉｌ−３６ｒ抗体の使用
|
|
BR112020016738A2
(pt)
|
2018-03-14 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada
|
|
WO2019185477A1
(fr)
|
2018-03-27 |
2019-10-03 |
Boehringer Ingelheim International Gmbh |
Composés dinucléotidiques cycliques contenant 2-aza-hypoxanthine ou 6h-pytazolo[1,5-d][1,2,4]triazine-7-one en tant qu'agonistes de sting
|
|
JP2021519279A
(ja)
|
2018-03-27 |
2021-08-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
修飾環式ジヌクレオチド化合物
|
|
EP3781941B1
(fr)
|
2018-04-20 |
2026-01-14 |
Janssen Biotech, Inc. |
Qualification de colonnes de chromatographie pour la production de mélanges d'anticorps anti-tnf
|
|
WO2019212253A1
(fr)
|
2018-05-02 |
2019-11-07 |
사회복지법인 삼성생명공익재단 |
Anticorps se liant de manière spécifique à c-met et utilisation associée
|
|
KR20210006412A
(ko)
|
2018-05-08 |
2021-01-18 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
디히드로피리미딘 유도체 및 hbv 감염 또는 hbv-유도성 질환의 치료에 있어서의 이의 용도
|
|
US20190345245A1
(en)
|
2018-05-11 |
2019-11-14 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
|
UA130542C2
(uk)
|
2018-05-16 |
2026-03-18 |
Янссен Байотек, Інк. |
Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
|
|
EP3793521A4
(fr)
|
2018-05-18 |
2022-02-23 |
Janssen Biotech, Inc. |
Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
|
|
EP3569618A1
(fr)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonisation d'anticorps cd73
|
|
MX2020012607A
(es)
|
2018-05-23 |
2021-01-29 |
Pfizer |
Anticuerpos especificos para gucy2c y sus usos.
|
|
KR102602329B1
(ko)
|
2018-05-23 |
2023-11-16 |
화이자 인코포레이티드 |
Cd3에 특이적인 항체 및 이의 용도
|
|
JOP20190116A1
(ar)
|
2018-05-24 |
2019-11-24 |
Janssen Biotech Inc |
الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
|
|
PE20211916A1
(es)
|
2018-05-24 |
2021-09-28 |
Janssen Biotech Inc |
Agentes aglutinantes del psma y usos de estos
|
|
CA3101271A1
(fr)
|
2018-05-24 |
2019-11-28 |
Janssen Biotech, Inc. |
Anticorps anti-cd3 et leurs utilisations
|
|
AU2019274782A1
(en)
|
2018-05-24 |
2020-12-03 |
Ares Trading S.A. |
Method for controlling the afucosylation level of a glycoprotein composition
|
|
WO2019231243A1
(fr)
|
2018-05-29 |
2019-12-05 |
사회복지법인 삼성생명공익재단 |
Cellule nourricière exprimant ox40l et procédé de culture de cellules tueuses naturelles l'utilisant
|
|
US20190365743A1
(en)
|
2018-05-30 |
2019-12-05 |
Hedgepath Pharmaceuticals, Inc. |
Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome
|
|
WO2019235839A1
(fr)
|
2018-06-05 |
2019-12-12 |
사회복지법인 삼성생명공익재단 |
Modèle animal de phénotype d'ophtalmopathie de graves, son procédé d'élaboration et procédé de recherche par criblage d'une substance thérapeutique contre l'ophtalmopathie de graves
|
|
CA3045370A1
(fr)
|
2018-06-08 |
2019-12-08 |
Pfizer Inc. |
Methodes de traitement de la maladie metabolique
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
CN113166972A
(zh)
|
2018-06-11 |
2021-07-23 |
耶鲁大学 |
新型免疫检查点抑制剂
|
|
GB201809700D0
(en)
|
2018-06-13 |
2018-08-01 |
Singapore Health Serv Pte Ltd |
IL-11 antibodies
|
|
GB201809699D0
(en)
|
2018-06-13 |
2018-08-01 |
Singapore Health Serv Pte Ltd |
IL-11 antibodies
|
|
EP3810609B1
(fr)
|
2018-06-18 |
2024-06-12 |
Janssen Pharmaceutica NV |
Dérivés de la pyrazole comme inhibiteurs de la malt1
|
|
AU2019289222B2
(en)
|
2018-06-18 |
2023-07-13 |
Janssen Pharmaceutica Nv |
Pyrazole derivatives as MALT1 inhibitors
|
|
CN112513017A
(zh)
|
2018-06-26 |
2021-03-16 |
爱尔兰詹森科学公司 |
二氢嘧啶衍生物及其在治疗hbv感染或hbv诱发疾病中的用途
|
|
JP7645076B2
(ja)
|
2018-06-27 |
2025-03-13 |
ベーリンガー インゲルハイム エルツェーファウ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
転写因子の使用によってタンパク質発現を増加させるための手段及び方法
|
|
WO2020006347A1
(fr)
|
2018-06-29 |
2020-01-02 |
Boehringer Ingelheim International Gmbh |
Anticorps anti-cd40 destinés à être utilisés dans le traitement d'une maladie auto-immune
|
|
US20200025776A1
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
|
|
US11053235B2
(en)
|
2018-08-09 |
2021-07-06 |
Janssen Sciences Ireland Unlimited Company |
Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
|
|
CN112912395B
(zh)
|
2018-08-20 |
2024-08-23 |
辉瑞公司 |
抗gdf15抗体、组合物和使用方法
|
|
US20200061015A1
(en)
|
2018-08-23 |
2020-02-27 |
Janssen Biotech, Inc. |
Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
|
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
AU2019326933B2
(en)
|
2018-08-28 |
2024-12-05 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds as Vanin inhibitors
|
|
EP3848388B1
(fr)
|
2018-09-05 |
2025-08-20 |
LG Chem, Ltd. |
Polypeptide de fusion comprenant une région polypeptidique pouvant être o-glycosylée
|
|
JP7654539B2
(ja)
|
2018-09-07 |
2025-04-01 |
ファイザー・インク |
抗αｖβ８抗体、組成物及びその使用
|